Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
about
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expressionAbl family kinases regulate endothelial barrier function in vitro and in micePhase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitorCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor GrowthDevelopment of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect.Effect of pazopanib on tumor microenvironment and liposome deliveryTailoring tyrosine kinase inhibitors to fit the lung cancer genome.Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.A rare case of osteonecrosis of the jaw related to imatinibTreatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.ROI for outlining an entire tumor is a reliable approach for quantification of lung cancer tumor vascular parameters using CT perfusionActivated c-Abl tyrosine kinase in malignant solid tumors.Interstitial Fluid Pressure Correlates Clinicopathological Factors of Lung Cancer.Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model.Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis.Molecular pathways and potential therapeutic targets in glioblastoma multiforme.Barriers to drug delivery in solid tumors.Vascular patterning and permeability in prostate cancer models with differing osteogenic properties.Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial groExploratory study on the correlation between 14 lung cancer-related gene expression and specific clinical characteristics of NSCLC patients.Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.Transport of drugs from blood vessels to tumour tissue.ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma
P2860
Q24306884-72AADF0C-C22B-4C41-82B0-F82F0B548B10Q24316240-1F6D9DFB-0FDF-4433-AC4D-824CAAABD019Q24594930-8CC016EF-1341-49DF-84A0-588E5C57E40DQ26774159-9321EE0B-02B9-4F2A-B1A2-F728E52CD731Q33457195-668A80C9-20D6-4442-96FE-C66A566F36BAQ33689872-D6C28473-560E-4E88-BE26-588CAB15A166Q34018204-617A0257-ABF8-424E-AE25-E62DA1CDF4B0Q34754045-91EC56C8-2FEB-4C32-8873-D85B3E8B2235Q36288883-397994E1-14EF-4F6A-88AD-6E7BCDF7D273Q36324677-FDFF6616-F780-4478-90A8-C98052A83A85Q36360226-6BD3FEC3-5F24-4B6E-A140-9BE34EA315F4Q36611170-133B7894-1196-4B5B-85FB-E86F92550712Q36861861-3AF8FC40-4F5F-4D5E-B76D-AE8AEF9B51FCQ37129818-7D1392B2-98C0-4428-AD3B-A54DE9EEECC2Q37186812-A32875DC-B849-4B9A-8118-3994653CA6BCQ37257191-1CAFC543-BAC8-48ED-866C-F2B6D0F7CF69Q37268818-DB0CE02E-6D1F-41DE-BE68-E2A64E078BE9Q37352000-0771D028-5ABF-4F49-A0BD-D9479E18C134Q38156191-1D145735-3043-4B95-958F-6530F93A513BQ38234567-61C646A3-05F1-48DD-8EBF-B4F10996996EQ39434282-91A20B34-3212-41D5-9628-9D2E7724D251Q39935853-685A6BD8-6321-4F6B-BF71-0A68FFF5401BQ41920903-A887A5A9-CAC1-436D-BCF8-E514B83E98C2Q43199207-A16EA0F2-4BDE-4BB9-9828-06422187144EQ45228150-2A8405A1-0906-42CE-A44E-BA17DE49C7F8Q50082408-4F732E53-9B3F-46F0-81B0-05685FF0E1FAQ54358602-48825D7D-DB0C-4145-983D-A5660EC62182Q57317511-3E2D6FC3-3CD1-4A30-BAB7-9A119B0F5006
P2860
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Treatment with Imatinib in NSC ...... and improvement of oxygenation
@ast
Treatment with Imatinib in NSC ...... and improvement of oxygenation
@en
Treatment with Imatinib in NSC ...... nd improvement of oxygenation.
@nl
type
label
Treatment with Imatinib in NSC ...... and improvement of oxygenation
@ast
Treatment with Imatinib in NSC ...... and improvement of oxygenation
@en
Treatment with Imatinib in NSC ...... nd improvement of oxygenation.
@nl
prefLabel
Treatment with Imatinib in NSC ...... and improvement of oxygenation
@ast
Treatment with Imatinib in NSC ...... and improvement of oxygenation
@en
Treatment with Imatinib in NSC ...... nd improvement of oxygenation.
@nl
P2093
P2860
P356
P1476
Treatment with Imatinib in NSC ...... and improvement of oxygenation
@en
P2093
G Vlahovic
J E Herndon
M W Dewhirst
Z N Rabbani
Z Vujaskovic
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603366
P407
P577
2006-09-26T00:00:00Z
P5875
P6179
1047071420